Patent intelligence · US
US 11274123
1,2,4-oxadiazole compounds as inhibitors of CD47 signalling
1,2,4-oxadiazole compounds as inhibitors of CD47 signalling
Patent details — US 11274123
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 15, 2022
- Expiration
- Mar 10, 2042
- Applicant
- Aurigene Discovery Technologies Limited
- Claims
- 17
- CPC classes
- A61K, A61K38/00, A61P, A61P25/28
Quick answer
US 11274123 (1,2,4-oxadiazole compounds as inhibitors of CD47 signalling) is held by Aurigene Discovery Technologies Limited. Status: granted. Granted Mar 15, 2022. Expires Mar 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aurigene Discovery Technologies Limited
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K38/00, A61P, A61P25/28, A61P31/04, A61P31/10
More from Aurigene Discovery Technologies Limited
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 11274123?
US 11274123 (1,2,4-oxadiazole compounds as inhibitors of CD47 signalling) is held by Aurigene Discovery Technologies Limited. Status: granted. Granted Mar 15, 2022. Expires Mar 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11274123?
Aurigene Discovery Technologies Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 11274123 expire?
Our index shows an expiration date of Mar 10, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.